Navigation Links
Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Date:9/17/2008

PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the UBS Global Life Sciences Conference being held from September 22-25, 2008 at the Grand Hyatt Hotel in New York City. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Wednesday, September 24, 2008, from 4:00 PM - 4:30 PM (ET).

To access a live webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
4. Pharmasset Receives Notice of Allowance
5. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
6. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
7. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
9. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...Abstinence is still the best policy , , RO...A new study from Mayo Clinic finds the use of the ...coholic hepatitis, an acute inflammation of the li...e results of the study are published in the Decemb...journal.org/ ). , , VIDEO ALERT: Additiona...
(Date:12/1/2008)...EGO, Dec. 1 Vical Incorp...pt of a $1.0 million milestone payment from Merck ...n of a Phase I clinical trial of an investigationa... vaccine is based on Vical,s DNA gene delivery tec...criptase (hTERT). hTERT is the subject of separate...
(Date:11/27/2008)...udy finds the majority of acute lymphoblastic leuk...nt at the time of diagnosis , , MEMPHIS, Te... at St. Jude Children,s Research Hospital have ide...cells of children with acute lymphoblastic leukemi...athway to designing treatments for ALL relapse in ...
(Date:11/25/2008)...ILLE, Ky., Nov. 25 Klei...eons performed the fifth U.S. hand transplant on M... Louisville,s Jewish Hospital Hand Care Center on ...an around noon and was completed shortly after 9 p...ttp://www.newscom.com/cgi-bin/prnh/20081125/DC4855...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Savannah Capital Management Announces 3rd Quarter Report on AMDL 28AMEX 3A ADL 29 2020 1New system for classifying infant lung disease developed 7270 1New system for classifying infant lung disease developed 7270 2New system for classifying infant lung disease developed 7270 3The World Economic Forum Announces Technology Pioneers 2008 3A Mondobiotech Selected 2016 1The World Economic Forum Announces Technology Pioneers 2008 3A Mondobiotech Selected 2016 2The World Economic Forum Announces Technology Pioneers 2008 3A Mondobiotech Selected 2016 3The World Economic Forum Announces Technology Pioneers 2008 3A Mondobiotech Selected 2016 4Categories Selected for the 2009 2825th 29 Japan Prize 7265 1Categories Selected for the 2009 2825th 29 Japan Prize 7265 2Categories Selected for the 2009 2825th 29 Japan Prize 7265 3
...weden, March, 9, 2007-Active Biotech (ACTI.ST), to...Phase Ib study of,TASQ, for the treatment of prost... dose of 1 mg/day of TASQ,was achieved, which corr...aximum tolerated dose (MTD) level of 0.5 mg/day. T...lation enables a dose,of 1 mg/day to be administer...
...(BUSINESS WIRE)--Mar 12, 2007 - Ceragenix Pharmace...mpany focused on,infectious disease and dermatolog...Ceragenin compound demonstrated virtually no biofi...yurethane catheters treated with Ceragenins,were s... with an,untreated catheter. At day 21, the cathet...
Other Medicine Technology:Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:12/1/2008)...END, Ind., Dec. 2 Patient satisfac...are on the rise according to a new report,from Pr...lse Report: Patient,Perspectives on American Heal...ies as a driver for improvement in patient service...2 million patients treated at more than,1,200 out...
(Date:12/1/2008)...IS, Dec. 2 While many Am...mic challenges including rising costs of,basic ne...ress Scripts,(Nasdaq: ESRX ) has expanded Rx Ou...rescription medicines. , (Logo: http://ww...LOGO ) , Lower-income consumers can now rec...
(Date:12/1/2008)...GO New research reveals that computed tomography ...py, has the potential to screen for two diseases a...which commonly affect adults over age 50. Results ... meeting of the Radiological Society of North Amer... to screening for colorectal cancer, we were able ...
(Date:12/1/2008)...k Warren Presents Award, Engages with President on...Home and Abroad During Saddleback Civil Forum on G...wire/ -- President George W. Bush was honored on t...the "International Medal of PEACE" given by Dr. Ri...during the Saddleback Civil Forum on Global Health...
Breaking Medicine News(10 mins):Health News:Outpatient Service Facilities Face Increasing Competition - Patient Perceptions More Important Than Ever 2Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 2Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 3Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 4Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5
... scientists have successfully converted human embr...e that in future, replacement cartilage could be g...and medical // problems, including sports injuries... replacements, and even for cosmetic and reconstru...
...nts in the United Kingdom may be at a high risk of...nducted by a team of researchers randomly on 250 G...eir // patients were overdosing on vitamins and re...e placing upon their body. A large number of pati...
...are developing tests that can identify the beginni...signs of the disease emerge. The researchers, who...annual meeting of the Society for Neuroscience in ...hem to single out people who went on to develop th...
...illicit use of drugs is on the rise in England, ac...0 admissions to the emergency department each year...with // patients visiting the emergency department...The doctor in charge of emergency care was also as...
Other Medicine News:Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Vitamin Abuse Syndrome In the UK 2Health News:Diagnosis of Alzheimer's years before clinical signs emerge 2
Nitinol Flat Wire Basket
A breakaway microwell EIA for the detection of toxins produced by Enterohemorrhagic E. coli
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity.
Medicine Products: